drugset
drugset / Trial / NCT04478825

Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis

NCT04478825 ↗

Phase 1 Terminated 2 enrolled Bridge Biotherapeutics, Inc. Covance · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an open label, single-arm, proof of mechanism study to explore the efficacy and safety of rectally administered BBT-401-1S in subjects with ulcerative colitis.

Timeline

Start
2021-06-01
Primary completion
2021-08-04
Completion
2021-08-24

Outcome

Outcome not reported

Stopped: “Internal Company Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject BBT-401-1S Peptide — Rectal

Indications

ulcerative colitis